ClinicalTrials.gg
Active, not recruitingNCT05359887ObesiPETUpdated Apr 29, 2026

PET-study on the Role of the Reward System in Weight Loss After Bariatric Surgery

An interventional study of standardized liquid mixed meal Nutridrink® in Obesity, sponsored by University Medical Center Groningen. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.

Planned enrollment
150th of 211
30 · median 58
Started
2022
with 11 others
No phase
128 of 248
17 open now
Primary completion
2026-12
later than 10 of 54 live
Registered
184th of 248
by date

Among the 248 studies in Obesity with a site in Netherlands, this one is the 150th largest by planned enrollment of the 211 interventional ones that give a count, is one of 12 that started in 2022, is one of 128 with no phase, reaches primary completion later than 10 of the 54 other live ones, and was the 184th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Obesity with a site in Netherlands, or all of them as a file.
02

Study summary

Bariatric surgery (BS) is currently the most effective treatment in severe obesity. However, a considerable percentage of patients undergoing BS fail to lose sufficient weight or regain weight after initial weight loss during long-term follow-up, which may be attributed to personality traits and pathological eating behaviour. Previous positron emission tomography (PET) studies have shown reduced dopamine D2 receptor availability in obese patients and upregulation of this availability following successful BS in the brain's reward system. Dopamine D2 receptor availability in patients with unsuccessful BS has not been investigated to date.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Reward system
  • PET-scan
  • [11C]-Raclopride
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bariatric surgery 24-36 months prior to the study
  • Adult (over 18y old)
  • Mentally capable to understand the consequences of the procedure and make his or her own choice without coercion
  • Able to undergo PET and MRI, according to the investigator's assessment
  • Native speaking
  • Able to participate in follow-up
  • Written

Exclusion criteria

Exclusion Criteria:

  • Presence of a axis 1 disorder
  • The use of drugs that bind to dopamine D2/3 receptors, including various classes of antipsychotics and antidepressants
  • History of stroke, brain tumor, Parkinson's Disease or dementia
  • History of head trauma with loss of consciousness
  • Alcohol or substance abuse in the last 6 months
  • Alcohol consumption 24h prior to PET scanning
  • Smoking or other forms of nicotine intake 12 hours prior to PET scanning
  • Use of anorectic drugs in the last 6 months
  • Current pregnancy
  • Medication for Diabetes Mellitus
  • Claustrophobia
  • The presence of implanted metal objects of the type which may concentrate radiofrequency fields or cause tissue damage from twisting in a magnetic field (such as certain implanted devices, shrapnel, ocular metal shavings)
  • Patients with a bodyweight > 200kg will be excluded to ensure the maximum load of the camera bed of the PET-scanner (227 kg) is not exceeded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Unsuccessful BS (Total Weight Loss (TWL) < 20%)

    Fifteen who had unsuccessful BS (Total Weight Loss (TWL) \< 20%)

    Other: standardized liquid mixed meal Nutridrink®

  • Experimental
    Successful BS (TWL > 25%).

    Fifteen who had successful BS (TWL \> 25%).

    Other: standardized liquid mixed meal Nutridrink®

Interventions

  • Otherstandardized liquid mixed meal Nutridrink®

    Administration of food in controlled situation

06

What researchers measure

Primary outcomes

  1. Change in [11C]-raclopride binding potential in the brain's reward system between study groups before and after a food challenge.

    Pre- and post-eating changes in dopamine D2 receptor availability as indexed by the \[11C\]-raclopride binding potential in the brain's reward system between subjects who underwent successful vs unsuccessful bariatric surgery

    Time frame: -50 minutes (before start of PET scanning), 0 minutes (during PET break, before mixed meal), 30 minutes (after second phase of PET-scanning)

Secondary outcomes

  1. The correlation between [11C]-raclopride binding potential in the brain's reward system and of questionnaires and diaries

    The correlation between questionnaires on eating habits (EDE-Q, REO, YFAS) and quality of life (OBESI-Q) in patients who had successful vs unsuccessful BS and \[11C\]-raclopride binding potential.

    Time frame: Pre-intervention

  2. The correlation between [11C]-raclopride binding potential in the brain's reward system and of gut hormones.

    The relation between fasting or fed (gut) hormone concentrations and dopamine D2 receptor availability in the reward system.

    Time frame: -50 minutes (before start of PET scanning), 0 minutes (during PET break, before mixed meal), 30 minutes (after second phase of PET-scanning), 60 - 90 - 120 minutes

07

Study locations

1 site
  • MCL
    Leeuwarden, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 48 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
May 4, 2022
StartActual
Dec 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05359887
Responsible party
Sponsor
First posted
May 4, 2022
Start date
Dec 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion